Novo Nordisk to create 6000 jobs by 2022


Danish insulin and diabetes specialist Novo Nordisk says it intends to employ 6000 more highly skilled workers within Denmark by 2022. Half of these new staff will work in R&D. The announcement bucks the trend of recent years in pharma, which has tended to see companies downsizing drastically and closing R&D sites.

The company used its announcement to call on the Danish government to prioritise investment in research-based training in the sciences to ensure that research-driven Danish companies can continue to grow. ‘It will be crucial for Novo Nordisk that Denmark educates world-class graduates but also focuses far more intently on attracting international talent,’ said the firm’s chief science officer, Mads Krogsgaard Thomsen in a statement.


Related Content

Novo Nordisk quits inflammation R&D and cuts jobs

3 September 2014 Business

news image

Firm will return to primary focus on diabetes and obesity

$100m of diabetes R&D in China

24 September 2012 Business

news image

Novo Nordisk will create 130–200 new research jobs

Most Read

UC Davis chemist sentenced to four years over explosion

19 November 2014 News and Analysis

news image

Postdoc sentenced over attempt to make explosive device and reckless disposal of hazardous waste

Spanish fly

10 October 2013 Podcast | Compounds

news image

Helen Scales looks at cantharidin, the active ingredient in this famous aphrodisiac

Most Commented

Beetle behind breath test for bank notes

17 November 2014 Research

news image

Photonic crystal inks inspired by longhorn beetle could help to fight counterfeiting

Bayer wins race to buy Merck & Co consumer care

9 May 2014 Business

news image

$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company